Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

Already making inroads as a treatment for HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo's Enhertu has now shown efficacy in tumours that express lower levels of HER2 – potentially ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

The drugmakers will explore the efficacy of Dato-DXd in combination with other drugs in PD-L1-expressing or EGFR-mutated NSCLC in these studies.

Additionally, Daiichi Sankyo and its Enhertu commercial partner AstraZeneca demonstrated excellent commercial decision-making by pursuing approval for the newly defined HER2-Low breast cancer ...

The campaign is presented by Daiichi-Sankyo and AstraZeneca, while Merck serves as a gold-level sponsor and Eli Lilly, Pfizer and Guardant come aboard as community sponsors. In the campaign’s ...

TROPION-Lung10 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus rilvegostomig as first-line treatment for advanced or metastatic nonsquamous NSCLC with high PD-L1 ...

datopotamab deruxtecan is one of the three lead ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced ...

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung ...

Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of ...

and being jointly developed by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). TROPION-Lung10 is evaluating datopotamab deruxtecan plus rilvegostomig, AstraZeneca’s PD-1/TIGIT bispecific ...